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Abstract
Regioselective modification of amino acids within the context of a peptide is common to a number
of biosynthetic pathways and many such products have potential as therapeutics. The ATP
dependent enzyme LynD heterocyclizes multiple cysteine residues to thiazolines within a peptide
substrate. The enzyme requires the substrate to have conserved N-terminal leader for full activity.
Catalysis is almost insensitive to immediately flanking residues in the substrate suggesting
recognition occurs distant from the active site. Nucleotide and peptide substrate co-complex
structures of LynD reveal the substrate leader peptide binds to and extends the β-sheet of a
conserved domain of LynD, whilst catalysis is accomplished in another conserved domain. The
spatial segregation of catalysis from recognition combines seemingly contradictory properties of
regioselectivity and promiscuity; it appears to be a conserved strategy in other peptide modifying
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enzymes. A variant of LynD that efficiently processes substrates without a leader peptide has been
engineered.
Introduction
There has been a surge in interest in the ocean as a source of new therapeutics1. This has in
part been stimulated by high profile successes and by belief that the less well-explored
marine environment contains many more unexploited resources2,3. Ribosomally synthesized
and post-translationally modified peptides (RiPPs) produced by marine organisms have been
shown to possess anti-tumour, anti fungal, antibacterial and antiviral properties4.
Cyanobactins, cyclic peptide natural products from cyanobacteria, are RiPPs in which one or
more core peptides (it is the core peptide which becomes a natural product) are embedded
into a larger precursor peptide. The most well-known example of this class are the
patellamides, whose biosynthetic pathway was one of the first cyanobactin pathways to be
described and cloned5-7. The precursor peptide has a conserved N-terminal leader, typically
around 40 residues, which is disposed of during maturation8. Characterized modifications of
the core peptide include heterocyclization (also known as cyclodehydration) of Cys (and in
some cases Ser/Thr) residues to oxazolines (and thiazolines) (Figure 1A), epimerization of
amino acids to give D-stereocenters, oxidation of these heterocycles to oxazoles and
thiazoles, Ser/Thr/Tyr prenylation and macrocycle formation5,9,10. The enzymes for each
natural product are named XxxY; where Xxx is three letter abbreviation of the natural
product (Pat, Lyn, Tru) and Y is a single letter that denotes the enzyme, A being the N-
terminal protease (removes leader peptide), G the macrocyclase / oxidase, F the prenylase
and D the cyclodehydratase8. The permissiveness of the modifying enzymes to sequence
changes in the core peptide has been elegantly demonstrated by the creation of large
libraries of novel macrocycles made in vivo by genetic engineering6,11. An alternative
combined in vivo and in vitro system for production of patellamides in larger quantities has
also been reported12 . In the patellamide pathway the protease PatA, the cyclodehydratase
PatD and macrocyclase PatG all recognize residues outside the core peptide to accomplish
their transformations13-17. The recognition beyond the functional group being modified that
governs the prenylase18,19, oxidase20 and hypothetical epimerase remain unknown.
Heterocyclization of core peptide Cys (and sometimes Ser/Thr) residues to thiazolines (and
oxazolines) by a highly conserved class of ATP and Mg2+-dependent YcaO-domain
containing cyclodehydratases (the D enzymes PatD, TruD, LynD etc) is presumed to be first
chemical transformation in patellamide-like products21,22. The site-selective introduction of
heterocycles into peptide backbones alters both the conformation and reactivity of peptides;
this tailoring of peptides is highly desirable in modifying their biological properties23. It has
long been known that the N-terminal leader of substrate peptides was key for processing by
TruD / PatD21,22 but no molecular insight has been forthcoming. The apo structure of the
cyanobactin heterocyclase TruD showed this enzyme to be a three-domain protein16. The
first two domains share structural but limited sequence homology with MccB (an
adenylating enzyme from the microcin pathway)24 and the third domain (the ‘YcaO’
domain) had, at that time, no homology to known structures16. Interestingly the putative
ATP binding site in TruD (based on homology with MccB and other adenylating enzymes)
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has two loop deletions that meant if ATP bound this domain it would do so differently than
in other adenylating enzymes16. The direct observation of pyrophosphate and AMP
production during enzyme turnover, coupled with the homology between TruD and MccB,
led us to propose an adenylating mechanism for the enzyme16, in contrast to the kinase
mechanism proposed for BalhD25,26(Figure 1B), a cyclodehydratase involved in thiazole/
oxazole-modified microcins (TOMM) biosynthesis - another product of the growing family
of RiPPs. BalhD is a YcaO domain and is homologous in sequence to the third domain of
the D enzymes. Analysis of both the BalhD and TruD has shown they operate with a
preferred order (start at C-terminus)16,27. A substrate recognition motif within the leader
peptide of PatE, the precursor peptide, has been identified (denoted ‘minimal leader’)16 and
this motif is conserved in all related precursor peptides (TruE, LynE etc)28. TruD was shown
to process the C-terminal cysteine of test peptides which lacked the leader, albeit more
slowly, but TruD was not, within the timescale of the experiment, able to process a second
‘internal’ cysteine16. A recent study reported that trans activation of the PatD enzyme by
exogenous leader peptide restored processing activity for internal cysteines29.
The structure of an E. coli YcaO domain bound to nucleotide has been reported (25 %
sequence identity to TruD)30. The residues that coordinate the AMP-PNP analog in this E.
coli YcaO domain are largely conserved in cyanobactin cyclodehydratases pointing to a
unified mechanism for all such YcaO domain proteins. In the absence of substrate E. coli
YcaO hydrolyzed ATP to AMP and pyrophosphate, echoing the finding from TruD16.
Here, we report three crystal structures of the cyanobactin heterocyclase LynD (highly
homologous to PatD and TruD) from the aestuaramide pathway (Lyngbya sp.). We used the
previously described modified PatE16 (denoted PatE′) for co-complex studies as it is a
substrate of LynD. LynE (the authentic LynD substrate) has an identical minimal leader
sequence28 to that identified in PatE16. Structures are reported for LynD/AMP/PatE′,
LynD/ADP PO43−/PatE′C51A and LynD/β,γ-imido-ATP/PatE′C51A co-complexes. The
structures confirm that LynD has a nucleotide-binding site in its third (YcaO) domain of
LynD, similar to that described for the E. coli YcaO structure30. The molecular basis of
leader recognition by LynD has been elucidated, rationalizing both cis / trans activation of
PatD and the molecular basis of the ‘minimal leader’. A novel LynD (FUSED LynD) has
been engineered, which no longer requires leader on the substrate peptide and this has
potential in biotechnology and chemical synthesis.
Results
Structure of LynD
Full-length LynD heterocyclase was expressed, purified and its ability to perform
heterocyclization reactions with a precursor peptide PatE′ in the presence of ATP/Mg2+
(Supplementary Results, Supplementary Table 1) confirmed as described previously16. PatE′
is 64 amino acids long, has a full leader but possesses a single core peptide (ITACITFC) and
C-terminal His6-tag. The retention time of LynD in gel filtration suggested LynD was a
dimer and diffraction quality crystals were only obtained when incubated with a nucleotide
and PatE′. The same orthorhombic form (but different unit cells) with two monomers in the
asymmetric unit was obtained for all three complexes (LynD/AMP/PatE′ 2.86 Å,
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LynD/ATP/PatE′C51A 2.14 Å, LynD/β,γ-imido-ATP/PatE′C51A 3.01 Å). The two
protomers are composed of the same three domains and form the same antiparallel dimer by
head-to-tail association of domains 1 and 2 with a large interface (buried surface area of
~3280 Å2) first seen for TruD16 (Figure 2A). The structure of LynD/AMP/PatE′ was
determined by molecular replacement using TruD (PDB 4BS9) as the search model and
partly refined. This structure was used as a search model for the 2.14 Å data, a complete
model was built and refined with these data and then molecular replaced into the lower
resolution data. Full structural statistics are given in Supplementary Table 2. PatE′ binds to
LynD in an identical fashion in all three structures and as the overall Cα rmsd between the
structures was low (Cα rmsd of ≤ 1.06) our discussion refers to the high resolution
LynD/ATP/PatE′C51A structure except where detailed. In LynD residues 6-143, 151-229,
240-336, and 342-775 in chain A and 4-226, 240-336, and 343-775 in chain B are ordered;
the missing residues are presumed to be disordered. As seen in TruD, a Zn2+ ion in domain
2 is coordinated in the same manner16. The structures locate both the catalytic site and
substrate recognition: The nucleotide at the active site is located in domain 3, while the
leader peptide is bound at the interface between domain 1 from one monomer and domain 3
from the other. Simple distance constraints suggest that processing of the core peptide must
occur in the same domain 3 that contacts the leader, and thus the dimer is a functional
requirement (Figure 2B). Key molecular interactions governing nucleotide and substrate
recognition have been identified.
Nucleotide binding site
Domain 3 (residues 316-775) is structurally homologous to the E. coli YcaO domain30 (Cα
rmsd of 2.34 over 282 residues) and binds nucleotide in an identical location. In LynD AMP
complex (Figure 2C), the adenosine ring N7 atom makes a hydrogen bond with the side
chain of Q415 and the N1 atom with N536. The ring sits between a cation-π stacking
interaction with R344 on one face and van der Waals interactions to C419 and T351 on the
other (Figure 2D). The lack of extensive hydrogen bond recognition of the ring is consistent
with ability of these enzymes to use other nucleotide triphosphates16. The O2′ and O3′
atoms of the ribose molecule form hydrogen bonds with the main chain of A534 and the side
chain of E426 whilst the α-phosphate makes a salt bridge with R636 and hydrogen bonds
with Q544 and S419 (Figure 2D), very similar to the E. coli YcaO domain30. The
recognition of the adenosine is subtly different in E. coli YcaO30 as the adenosine ring has
been built in a different conformer in this structure.
The LynD ADP PO43− (Figures 2D, 2E and 2F) and AMP-PNP (Figure 2G) complexes
inform about the binding of the β and γ phosphates; the phosphate in the ADP PO43−
structure, we assume mimics the γ phosphate of ATP. There are differences in the precise
positions of the β and γ phosphates but the similarities are informative; in both structures a
Mg2+ ion, coordinated by E640, binds the β and γ phosphates and a second Mg2+ ion, bound
by E548, ligates the β phosphate (Figure 2D). In the ADP PO43− structure the second Mg2+
ion bridges the β and γ phosphate (Figure 2D). These two ions are also found in the E. coli
YcaO complex30, and are coordinated by equivalent glutamate residues. In the ADP PO43−
complex a third Mg2+ is present, which is coordinated by E423 and bridges the β and γ
phosphates (Figure 2D). In addition to the metal ions, the β phosphate has salt links with
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R636 and K409, whilst the γ phosphate salt bridges with R552 and R427 (Figure 2D). Very
similar interactions are seen in the AMPCPP complex of E. coli YcaO30. The ADP PO43−
has an unusual arrangement of Mg2+ ions, which may be a reflection of the 150 mM Mg
formate present in the crystallization buffer.
Key residues for catalysis and nucleotide binding
Cyclodehydration of cysteine/serine/threonine proceeds via attack on the nucleotide
triphosphate by a hemiorthoamide intermediate (Figure 1B). Our crystal structures reveal the
orientation of the nucleotide within the active site, relative to the incoming substrate, is such
that the α–phosphate is occluded from attack by the hemiorthoamide, thus precluding an
adenylation mechanism that we had previously proposed16. To ensure the observed
orientation of the nucleotide is mechanistically relevant and to eliminate any possibility it is
an artifact of crystallization, residues identified as binding to nucleotide binding were
mutated, and the subsequent mutants were tested for their ability to bind ATP/AMP and to
process substrate PatE′. Nucleotide binding data for LynD and mutants at the active/
nucleotide binding site and their ability to process substrates are shown in Table 1 and
Supplementary Figure 2 (MS/MS in Supplementary Figure 3 and Supplementary Tables 1
and 3). K409A processes PatE′ overnight to give two heterocycles, whilst K409E slows
down the reaction such that only one heterocycle is observed overnight (Supplementary
Table 1). Both mutants reduce binding to ATP and AMP below our isothermal calorimetry
(ITC) detection limits (usually around 2 mM). Two mutants R636A and R636E slow down
the reaction rate and impact observed processivity giving a mixture of 0, 1 and 2
heterocycles. Both mutants show a reduction in AMP binding to below ITC detection limits.
ATP binding to R636E was not detected by ITC, whilst R636A gave a complex ITC trace
with ATP that we have been unable to interpret. R427E slows down the reaction giving a
mixture of 1 and 2 heterocycles and retains AMP binding but eliminates detectable ATP
binding. Our assays typically use 5mM ATP; when this was reduced to 500 μM ATP a
reduction in rate of heterocyclization was observed for the LynD K409A mutant
(Supplementary Figure 4). E423R was completely inactive in our assay. All binding and
activity data support the orientation of the nucleotide within the crystal structure and rule out
an adenylation mechanism16. As with TruD16, LynD was observed to produce AMP (not
ADP), pyrophosphate (PPi) and phosphate when incubated with PatE′ and like YcaO30 the
same products were produced in the absence of substrate (Supplementary Figure 5A).
Following the procedure described in the BalhD study26 PatE′ we observed 18O
incorporation not only into Pi as described before26 but also into PPi (Supplementary
Figures 5B and 5C).
Leader peptide recognition by LynD
Only residues 21-35 of PatE′ are ordered in the structure: Q21 to S23 adopt a coil, S24 to
E28 adopt a helical turn, S30 to A33 adopt a β-strand conformation and L34 and G35 adopt
a coil (Figure 2H). The β-strand adds to the three-stranded anti-parallel β-sheet in domain 1
of LynD, converting it to a four-stranded anti-parallel β-sheet. In addition to β-sheet
hydrogen bonds the side chains of PatE′ E28 and E31 make both salt bridges and hydrogen
bonds with LynD Q47 (main chain), side chains of Y39 and R74 (Figure 2H). Both L26 and
L29 of PatE′ insert into hydrophobic pockets in Domain 1 of LynD (Figure 2H). The
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interactions provide a structural rationale for the minimal leader (residues 26 to 34 of PatE)
and site directed mutants previously reported16. LynD/PatE′ interaction affinities were
measured for a number of mutants of LynD (Table 2, Supplementary Table 1 and
Supplementary Figure 6). In the apo structure of TruD16 residues 371–415 (LynD
numbering) in Domain 3 were disordered but in LynD these are now ordered forming a
strand turn helix strand motif that makes the entrance to and part of the nucleotide binding
site. We suggest it is the leader peptide that leads to this ordering of LynD by reducing the
volume available for this region and secondly by making specific contacts; a salt bridge
between PatE′ E32 and LynD R399 and a hydrophobic cluster of PatE′ L34 with V217 and
L398 of LynD. These interactions depend upon the dimer, as it is the other subunit of LynD
which supplies these residues and which is ordered by the leader peptide (Figure 2H). The
extended β-sheet interaction between the leader and domain 1 we observe is similar to that
observed in the lantibiotic dehydratase substrate complex32.
Trans and cis activation of LynD by the leader
Overnight incubation of LynD with a short test peptide ITACITFCAYDG (mimicking the
core peptide and C-terminal macrocyclization signature of PatE) in the absence of leader
predominantly yields species containing only one heterocycle (Figures 3A and B) as
previously reported for TruD16. However co-incubation with exogenous full-length PatE
leader (up to the core peptide) or minimal leader accelerates the turnover of the test peptide
(6.7- and 5.0-fold, respectively), such that both heterocycles are observed overnight (Figure
3A and Supplementary Figure 7). The acceleration was more pronounced with the full-
length leader peptide than with the minimal leader peptide and reproduces a previous report
of trans activation of PatD by full-length leader29. In our hands this trans activation
remained slower than seen for full length PatE′. Guided by structural analysis, the leader
peptide (residues 21 to 38) was fused to the N-terminus of LynD to construct a self (cis)
activating enzyme (LynDfusion). This engineered enzyme expressed to a higher soluble
yield than native protein and ran normally as a dimer on gel filtration (Supplementary Figure
1). It processed both cysteines in the test peptide at a rate comparable to wild-type LynD
with the full length PatE′ substrate (Figure 3, Supplementary Figures 7 and 8) and we have
also demonstrated activity on a selection of short peptides (Supplementary Figures 9A-D).
In addition we show LynDfusion can also process full-length PatE′ substrate at a similar rate
to wild-type LynD (Supplementary Figure 9E).
Discussion
The ability of heterocyclases to separate recognition from the catalytic site is highly
desirable in biotechnology, conferring specificity by recognizing an invariant leader but
tolerating a wide range of residues adjacent to the target cysteine (or serine/threonine). Such
spatial separation and use of a leader is a feature of other post translational modifying
enzymes such as those found in the lantibiotic pathway35,36. Our structural data of the LynD
complexes has enabled us to formally identify both the active site and the region responsible
for substrate recognition in the PatD class of cyclodehydratases.
These data revealed that ATP binds in domain 3, (the conserved YcaO domain30) (Figure
2D). Residues involved in nucleotide binding were identified, and mutational analysis of
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these residues confirmed the nucleotide binding observed in the crystal structure to be
correct. In these models structural shielding of the α–phosphate from the substrate peptide
makes our previous suggestion of an adenylating mechanism untenable16, whereas the
exposed γ–phosphate does support a kinase mechanism26. However a simple kinase
mechanism does not explain the observations that TruD16 produces AMP and PPi during
turnover, as does LynD (both in the presence and absence of substrate) and the related YcaO
enzyme produces AMP and PPi in the absence of substrate30.
The leader peptide of the substrate is not required for processing of the terminal cysteine of
the core peptide but it is essential for meaningful processing of internal cysteine residues
(detectable within hours)16,29,37 (Figure 3 and Supplementary Figure 7). The LynD substrate
complexes provide insight into the molecular details of substrate recognition, and the role of
the leader peptide in efficient processing of heterocyclizable residues. LynD uses the β-sheet
of domain 1 to bind a conserved region within the leader of PatE′ (Figure 2H), similarly to
the lantibiotic dehydratase enzyme32. By anchoring the substrate peptide it converts an
intermolecular reaction into an intramolecular one. With the concomitant reduction in the
entropy penalty and increase in local concentration, these two factors accelerate catalysis of
both first and second heterocyclization (Figure 3). The substrate leader peptide also makes
contacts with domain 3, the catalytic domain, where it stabilizes a loop involved in the
active site. Importantly the leader peptide bridges domain 1 of LynD from one monomer to
domain 3 of LynD from the other monomer (Figure 2H). This is reminiscent of but different
from the MccB system, where domain 1 also acts a peptide clamp within a dimeric
arrangement. However in MccB the region of domain 1 and the interactions between its
‘leader’ peptide are different from that observed here24. The BalhC protein, which is
required for efficient heterocyclization of cysteine residues in leader containing linear
peptides by BalhD, clearly contains the peptide clamp domain and we propose it will operate
in similar manner. The presence of a structurally and functionally conserved peptide clamp
domain in three different enzymes that operate on different substrates suggests that the
peptide clamp may be general motif for peptide processing enzymes that utilize leader
peptides for recognition. This idea is supported by the observation of the same peptide
clamp in the nisin dehydratase substrate complex32. The low level of sequence homology
between MccB and TruD prevented confident identification of the conserved nature of the
peptide clamp but with multiple structures of this domain, identification of homologs is now
more reliable.
The stabilization of the active site loops by the leader peptide offers a molecular rational for
the trans activation of PatD by the leader peptide29 and a molecular route by which catalysis
and substrate binding/product release may be correlated. We show that the trans effect can
be observed even with a very small minimal leader, but stronger trans activation occurs with
a full-length leader (Figure 3 and Supplementary Figure 7). Following the example from
lantibiotic synthetase where the need for a peptide substrate leader was removed by fusing
the leader to the lantibiotic synthetase enzyme38, an engineered LynD was designed based
on our structural and biochemical insights into the role of the leader in LynD (Figure 4). The
fused enzyme (LynDfusion) was indeed as active at processing two cysteines within a short
test peptide ITACITFCAYDG as native LynD with PatE′ substrate (Figure 3 and
Supplementary Figure 7). Additionally, LynDfusion was able to process PatE′ as efficiently
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as wild-type LynD during an overnight incubation (Supplementary Figure 9E), which is
encouraging given the much higher expression of LynDfusion compared with LynD in our
hands. We confirmed the utility of the enzyme by evaluating it with other short peptide
substrates with seven, eight or nine core peptide residues including one with three cysteines
(Supplementary Figure 9A-D). The introduction of multiple heterocycles into a simple,
short, linear peptide is a desirable chemical modification and requires enzymes. To this
point, the substrate peptide would need at least 15 N-terminal residues added to ensure
complete processing. Since these residues are discarded in making the final product, such
‘waste’ makes the chemical synthesis of the peptide substrates unattractive and favors
bacterial production. However, the newly engineered LynD can act on peptides with no
leader and for those products where macrocyclization is required only three C-terminal
residues (AYD), which are disposed of, are required. This enables the chemical synthesis of
substrates, rather than biological production, which is typically higher yielding and permits
greater diversity through the introduction of multiple non-natural amino acids, providing the
potential for the generation of a large variety of bio-active peptides.
Materials and methods
Protein cloning, expression and purification
Codon-optimized full-length LynD (Lyngbya sp. PCC 8106) with an N-terminal TEV
protease-cleavable His6-tag was purchased from DNA2.0 in the pJexpress411 plasmid. The
protein was expressed in Escherichia coli BL21 (DE3) grown in auto-induction medium39
for 48 h at 20 °C. Cells were harvested by centrifugation at 4,000 × g, 4 °C for 15 min and
re-suspended in lysis buffer (500 mM NaCl, 20 mM Tris pH 8.0, 20 mM imidazole and 3
mM β-mercaptoethanol (BME)) with the addition of complete EDTA-free protease inhibitor
tablets (Roche) and 0.4 mg DNase g-1 wet cells (Sigma). Cells were lysed by passage
through a cell disruptor at 30 kPSI (Constant Systems Ltd) and the lysate was cleared by
centrifugation at 40,000 × g, 4 °C for 20 min. The cleared lysate was applied to a Nickel
Sepharose 6 Fast Flow (GE Healthcare) column pre-washed with lysis buffer and protein
eluted with 250 mM imidazole. The protein was then passed over a desalting column (Desalt
16/10, GE Healthcare) in 100 mM NaCl, 20 mM Tris pH 8.0, 20 mM imidazole, 3 mM
BME. Tobacco etch virus (TEV) protease was added to the protein at a mass-to-mass ratio
of 1:10 and the protein digested for 2 h at 20 °C to remove the His6-tag. Digested protein
was passed over a second Ni-column and the flow-through loaded onto a monoQ column
(GE Healthcare) equilibrated in 100 mM NaCl, 20 mM Tris pH 8.0, 3 mM BME. Protein
was eluted from the monoQ column through a linear NaCl gradient, eluting at 250 mM
NaCl. Finally, the protein was subjected to size-exclusion chromatography (Superdex™
200, GE Healthcare) in 150 mM NaCl, 10 mM HEPES pH 7.4, 1 mM TCEP, and
concentrated to 8 mg mL−1. Integrity and identity were confirmed by SDS_PAGE and mass
spectrometry.
PatE′ was synthetically produced in the pBMS vector (a gift from H. Liu) with a C-terminal
His6-tag and expressed in Escherichia coli BL21 (DE3) cells grown in auto induction
medium39 for 24 h at 30 °C where the protein was driven to inclusion bodies. Amino acid
sequence of PatE′:
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MDKKNILPQQGQPVIRLTAGQLSSQLAELSEEALGDAGLEASKITACITFCAYDGEL
EHHH HHH Cells were harvested by centrifugation at 4,000 × g for 15 min at 4 °C. Cells
were re-suspended in urea lysis buffer (8 M urea, 500 mM NaCl, 20 mM Tris pH 8.0, 20
mM Imidazole and 3 mM β-mercaptoethanol (BME) and lysed by sonication at 15 microns
(SoniPrep 150, MSE). The lysate was cleared by centrifugation at 40,000 × g, 20 °C for 20
min followed by passage through a 0.45 μm filter. The cleared lysate was applied to a Ni-
sepharose FF column (GE Healthcare) pre-washed with urea lysis buffer and protein eluted
with 250 mM imidazole. The protein was then supplemented with 10 mM DTT and
incubated at room temperature for 2 h before size-exclusion chromatography (Superdex™
75, GE Healthcare) in 150 mM NaCl, 10 mM HEPES pH 7.4, 1 mM TCEP. Peak fractions
were pooled and concentrated to 1 mM.
To generate full length leader peptide for trans activation studies the PatE′ sequence was
mutated at 4 positions: D2Y, K3E, K4E and R16E. This quadruple mutant (PatE′4) was
expressed and purified as described for PatE′, and subjected to heterocyclization tests to
ensure normal processing. The mutations K3E, K4E, and R16E enable full-length leader to
be retained following digestion of PatE′4 with trypsin (D2Y permits quantification of the
leader peptide). PatE′4 was digested with 1/100 trypsin at 37 °C, 300 rpm for 3 h, and
subsequently applied to a Ni-sepharose FF column (GE Healthcare) equilibrated in 150 mM
NaCl, 10 mM HEPES pH 7.4, 1 mM TCEP. The flow-through was collected, which was
confirmed to contain full-length PatE′4 leader peptide by mass spectrometry, and
concentrated to 1 mM.
LynD and PatE point mutants were produced using the Phusion® site-directed mutagenesis
kit (Finnzymes) following the manufacturer’s protocol. All mutant proteins were expressed
and purified as above. LynD fusion enzyme was produced by adding residues 21-38 of the
PatE leader and an eleven residue long linker to the N-terminus of LynD via PCR. The
protein was expressed and purified as described for native LynD above.
Protein sequence of LynD fusion protein:
MSHHHHHHDYDENLYFQGSQLSSQLAELSEEALGDAGAGAGAGAGAGAMQSTPLLQIQP
HFHVEVIEPKQVYLLGEQANHALTGQLYCQILPLLNGQYTLEQIVEKLDGEVPPEYIDYVLE
RLAEKGYLTEAAPELSSEVAAFWSELGIAPPVAAEALRQPVTLTPVGNISEVTVAALTTALR
DIGISVQTPTEAGSPTALNVVLTDDYLQPELAKINKQALESQQTWLLVKPVGSVLWLGPVF
VPGKTGCWDCLAHRLRGNREVEASVLRQKQAQQQRNGQSGSVIGCLPTARATLPSTLQTG
LQFAATEIAKWIVKYHVNATAPGTVFFPTLDGKIITLNHSILDLKSHILIKRSQCPTCGDPKIL
QHRGFEPLKLESRPKQFTSDGGHRGTTPEQTVQKYQHLISPVTGVVTELVRITDPANPLVHT
YRAGHSFGSATSLRGLRNTLKHKSSGKGKTDSQSKASGLCEAVERYSGIFQGDEPRKRATL
AELGDLAIHPEQCLCFSDGQYANRETLNEQATVAHDWIPQRFDASQAIEWTPVWSLTEQT
HKYLPTALCYYHYPLPPEHRFARGDSNGNAAGNTLEEAILQGFMELVERDGVALWWYNR
LRRPAVDLGSFNEPYFVQLQQFYRENDRDLWVLDLTADLGIPAFAGVSNRKTGSSERLILG
FGAHLDPTIAILRAVTEVNQIGLELDKVPDENLKSDATDWLITEKLADHPYLLPDTTQPLKT
AQDYPKRWSDDIYTDVMTCVNIAQQAGLETLVIDQTRPDIGLNVVKVTVPGMRHFWSRFG
EGRLYDVPVKLGWLDEPLTEAQMNPTPMPF
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Preparation of test substrates for LynDfusion enzyme
PatE′ variants with seven (PatE′-IACITFC) and nine (PatE′-IITACIMAC) core peptide
residues, and one with three cysteines (PatE′-ICACITFC) in the core peptide were cloned,
expressed and purified as described for PatE′. Each peptide was digested with 1/100 trypsin
at 37 °C, 300 rpm for 3 h and subsequently purified using size-exclusion chromatography
(Superdex™ 30, GE Healthcare) in 150 mM NaCl, 10 mM HEPES pH 7.4, 2 mM TCEP.
Heterocyclization reactions
For all heterocyclization reactions, 100 μM PatE′ (and variants,) was incubated with 5 μM
enzyme in 150 mM NaCl, 10 mM HEPES pH 7.4, 1 mM TCEP, 5 mM ATP and 5 mM
MgCl2 for 16 h at 37 °C. Samples were analyzed by ESI or MALDI MS (LCT, Micromass
or 4800 MALDI TOF/TOF Analyzer, ABSciex). For cis trans activation studies, 100 μM
ITACITFCAYDG synthetic test peptide (Peptide Protein Research Ltd) was reacted with 5
μM heterocyclase enzyme in the presence and absence of 5.5 μM LAELSEEAL synthetic
peptide, or 5.5 μM full-length PatE′4 leader peptide. The reaction was carried out in 150
mM NaCl, 10 mM HEPES pH 7.4, 1 mM TCEP, 5 mM ATP and 5 mM MgCl2 for 16 h at
37 °C and analyzed as above.
To assess the relative rates of heterocyclization under various conditions, heterocyclization
reactions were monitored at regular intervals using MALDI TOF MS. In each case, reactions
of PatE′ or ITACITFCAYDG synthetic peptide were prepared as described and incubated at
37 °C prior to addition of LynD (wild-type, mutants and fusion) allowing a 0 time-point to
be recorded. Time points for each reaction were recorded as follows: For PatE′ with LynD
(standard conditions), and ITACITFCAYDG with LynD fusion, the reaction was monitored
after 1, 5, 10, 15, 20, 30, 45, 60, 90, 120 and 180 minutes; For ITACITFCAYDG with LynD
in the absence and presence of either minimal leader LAELSEEAL peptide, or full length
PatE′4 leader peptide, the reaction was monitored after 15, 30, 60, 120, 240 and 1440
minutes; For PatE′ with wild-type LynD and LynD K409A with 500 μM ATP, the reaction
was monitored after 10, 30, 60, 120 and 360 minutes. Reactions were set up in triplicate, and
each sample was analyzed by MALDI TOF MS in triplicate (9 spectra recorded in total for
each reaction at each time point). For each time point, the total ion count for each species (0,
1 and 2 heterocycles) was recorded, averaged and the percentage of each species was
calculated. The rate of each reaction relative to the wild-type reaction (PatE′ + LynD) was
determined.
LC-MS of reaction mixtures was performed on a Waters LC-MS system (LCT mass
spectrometer and 2795 HPLC) using a Waters MassPrep column (2.1 × 10 mm). Solvent B
was 0.1% formic acid and Solvent A was MeCN containing 0.1% formic acid. Gradient 0 -
0.5min 98 % B, 0.5 - 2.5 min linear to 2 % B, 2.5 - 4.5 min 2 % B, 4.5 - 4.6 min linear to 98
% B, 1.6 - 12 min 98 % B at 0.05 ml min-1. The following conditions were used on the mass
spectrometer: ESI +ve, capillary voltage 3.5 kV, cone voltage 40 V, mass range 500-2500
m/z, RF lens 500. The spectra were combined across the eluted protein peak and the charged
ion series processed using Water’s MaxEnt algorithm to give protein mass, using peak width
at half height on the strongest peak in the ion envelope. The data was calibrated externally
against horse heart myoglobin (16,951.5 Da).
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MALDI MS was acquired using a 4800 MALDI TOF/TOF Analyzer (ABSciex, Foster City,
CA) equipped with a Nd:YAG 355 nm laser in linear mode and calibrated using the [M+H]+
and [M+2H]2+ peaks of ubiquitin. The spot was analyzed in positive MS mode between
3000 and 10000 m/z, by averaging 1000 laser spots.
Fragmentation MS of the peptides were carried out on an ABSciex 5600 mass spectrometer
with Eksigent nanoLC and ThermoScientific Aclaim Pepmap RSLC column 75uM ×
150mm. Trap and elute methodology was used with a 6 minute trap wash. Trapping solvent
A was 98 % water, 2 % MeCN, 0.05 % Trifluoroacetic acid. Gradient solvent A was 98 %
water, 2 % MeCN, and 0.1 % formic acid and gradient solvent B was 98 % MeCN, 2 %
water, and 0.1 % formic acid. Gradient 0 -0.5 min 5 % B, 0.5 - 5 min linear to 40 % B, 5 - 6
min linear to 95 % B, 6 - 9 min 95 % B, 9 - 10 min linear to 2 % B, hold at 2 % B until 20
mins at 300 nl min−1, and 45 °C. The following conditions were used on the mass spec: ESI
+ve, 0.25 s MS accumulation and 0.15 s MSMS accumulation, collision energy of 45 V with
rolling collision energy optimization applied. The data was calibrated externally prior to
analysis with 8 peptides from a tryptic digest of 25 fmol μl−1 β-galactosidase.
MALDI mass spectrometry for the time course was carried out on an ABSciex 4800
MALDI TOF/TOF mass spectrometer. 0.5 μl of sample was co-spotted with 0.5 μl of matrix
(10 mg ml−1 alpha cyano- 4-hydroxycinnamic acid in 50% MeCN and 50% 0.1 % TFA) and
the sample left to dry. Spectra were collected over the range 500 – 4000 m/z (reflectron for
peptides < 4000 m/z) or 3000 – 10000 m/z (linear for peptides > 4000 m/z) with 20
subspectra of 50 shots accumulated randomly across the spot. The data was calibrated
externally prior to analysis with 6 peptides from ABSciex standard 6 peptide mix (PN
4465940) in reflectron or the [M+H]+ and [M+2H]2+ peaks of ubiquitin in linear.
Crystallization, data collection, and crystallographic analysis
Co-crystallization trials of LynD with various peptide and nucleotide substrates were set up
at 7.5 mg ml−1 LynD with a 1.1 molar excess of PatE′ (or variants), 5 mM nucleotide and 3
mM MgCl2. LynD crystals in complex with PatE′-C51A and ATP were obtained in 16 %
PEG 3350, 0.1 M Mg formate. The crystals were cryoprotected in 37 % PEG 3350, 0.1 M
Mg formate, 1 mM ATP and flash-cooled in liquid nitrogen. These crystals belonged to
space group P212121 with cell dimensions a = 81.8 Å b = 116.1 Å, c = 183.5 Å. Diffraction
data was collected at Diamond beamline I24 at 100 K and processed with Xia240..
LynD crystals in complex with PatE′ and AMP were obtained in 13 % (w/v) PEG 3350, 0.1
M Tris pH 8.5, 0.2 M CaCl2 and 0.6 % (w/v) myo-inositole. The crystals were cryoprotected
in 35 % PEG 4000, 0.2 M CaCl2, 0.1 M Tris pH 8.5, 1 mM AMP and flash-cooled in liquid
nitrogen. These crystals belonged to space group P212121 with cell dimensions a = 65.8 Å b
= 152.8 Å, c = 182.8 Å. Diffraction data was collected at Diamond beamline I02 at 100 K
and processed with Xia240. LynD crystals in complex with PatE-C51A and β–γ-imido-ATP
were obtained in 28 % PEG 4000, 0.1 M Tris pH 8.9, 0.2 M LiSO4. The crystals were
cryoprotected in 40 % PEG 4000, 0.1 M Tris pH 8.9, 5 mM β–γ-imido-ATP and flash-
cooled in liquid nitrogen. These crystals belonged to space group P212121 with cell
dimensions a = 65.9 Å b = 152.9 Å, c = 182.5 Å. Diffraction data was collected at ESRF
beamline ID29 at 100 K and processed with Xia240.
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The structure of LynD in complex with PatE′ and AMP was determined by molecular
replacement using Phaser41,42 with TruD as a search model (PDB: 4BS9). The partially
refined structure was then used as a search model for the remaining structures. In each case,
complete manual rebuilding was performed with COOT43 and refinement was performed
using CCP4 REFMAC544 and Phenix Refine45. The statistics of data collection and
refinement are summarized in Supplementary Table 2. All molecular graphics figures were
generated with the program Pymol46.
NMR of ATP in the presence of LynD
31P observed NMR spectra were acquired using 1024 scans on a Bruker AVANCE III 500
MHz spectrometer equipped with a room temperature BBFO+ probe. Composite pulse
sequence ‘waltz-64’ was used for 1H power-gated broadband decoupling.
Selective 18O labeling of PatE′
PatE′ was selectively 18O labeled at the carbonyl of the residue preceding cysteines based on
a protocol described in a study of BalhD26. PatE′ was heterocyclized as described and the
reaction mixture was purified using size-exclusion chromatography (Superdex™ 75, GE
Healthcare). Pure heterocyclized-PatE′ was concentrated to 0.5 mL and dried to a powder
using a Thermo Savent Speed Vac. To accomplish selective 18O labeling the dried sample
was re-suspended in H218O supplemented with 0.1 % formic acid to hydrolyze the
heterocycles, and incubated at 20 °C. The ring opening was followed using MALDI TOF
MS. Once complete, selectively labeled 18O-PatE′ was dialyzed into 150 mM NaCl, 10 mM
HEPES pH 7.4, 1 mM DTT. To ensure all traces of acid and H218O were removed the
sample was dialyzed 3 × 1:1000 (2 × 2h followed by o/n). The dialyzed sample was
recovered, diluted to 7.5 mL in 8M urea containing 10 mM DTT and passed through a
Superdex™ 75 size-exclusion column (GE Healthcare) pre-equilibrated in 150 mM NaCl,
10 mM HEPES pH 7.4, 1 mM DTT to yield pure 18O2-PatE′ as confirmed by mass
spectrometry.
Identification of 18O Pyrophosphate
Purification of pyrophosphate from heterocyclization reactions was achieved by passing the
reaction mixture through a 5 kDa cut-off protein concentrator. The flow-through was applied
to CaptoQ resin (GE Healthcare), washed with 15 column volumes dH2O and
pyrophosphate eluted with 1M Na acetate pH 7.0.
Accurate mass measurements were carried out on ABSciex 5600 mass spectrometer with
nanospray source. Samples were diluted 50% with ACN and infused at 1ul/min using the
inbuilt syringe pump. Negative ionization spectra were collected from 60- 400m/z in MS
mode. Masses 176.9 and 178.9 m/z were isolated in Q1, fragmented with collision energy
30V in Q2 and the fragments measured from 50-200m/z on the TOF analyzer. The TOF was
externally calibrated with a mixture of Periodate (190.8847 m/z) and sulphanilic acid
(172.0074 m/z)
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ITC analysis of LynD (and mutants) with substrate peptide, and nucleotide
ITC experiments were performed using a VP-ITC instrument (MicroCal) in
heterocyclization reaction buffer (150 mM NaCl, 10 mM HEPES pH7.4, 1mM TCEP)
supplemented with 5 mM MgCl2. For substrate binding experiments a cell solution of 10 μM
LynD (and mutants) and a syringe solution of 150 μM PatE′ (and mutants) were prepared by
diluting protein and peptide with the buffer used for dialysis. For nucleotide binding
experiments, the cell concentration was increased to 20 μM, and the ATP/AMP
concentration in the syringe solution was 300 μM. Substrate, and ATP experiments were
performed at 20 °C, and AMP experiments at 25 °C. Cell and syringe solutions were
degassed for 15 min at 18 and 23 °C. Titration method was as follows: one injection of 2 μl
followed by injections of 5 μl at 0.5 μl/min, with a delay of 4 min between every injection.
The stirring speed was 307 rpm throughout. Raw data was processed using MicroCal Origin
software, and the baseline was adjusted and the integrations limits were selected manually.
Data was non-linearly fitted to the one-site model (Origin) setting the stoichiometry to 1;
allowing the stoichiometry to refine gave values above 0.9 and a two site model gave
meaningless fits.
Database entries
PDB codes 4v1v 4v1u and 4v1t.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. The heterocyclase reaction
A Cartoon schematic summarizing the processing cysteine residues within the core peptide
of PatE precursor peptide by the ATP-dependent cyclodehydratase (heterocyclase) enzyme
LynD, highlighting the defined order of heterocyclization. The enzyme works by binding
substrate, processing a single heterocycle then dissociating, this is denoted by the arrows in
the diagram.
B The chemical steps in cyclodehydration begin with abstraction of the sulfhydryl proton
followed by attack at the adjacent (N-terminal) carbonyl carbon generating a
hemiorthoamide. In an irreversible step this intermediate attacks ATP, and the resulting
phosphate species is eliminated, forming a thiazoline. Broadly there are three possible routes
by which ATP reacts: an adenylation mechanism where X = O and Y= PPi; a kinase
mechanism where X = PPi and Y =O; and a pyrophosphorylation mechanism where
X=Y=PO3.
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Figure 2. Crystal structures of LynD complexes
A Cartoon representation of the LynD/ATP/PatE′C51A complex structure. LynD forms a
functional dimer, with monomers colored green and cyan. The ordered residues of PatE
′C51A are shown in yellow and magenta. ATP bound in domain 3 is shown as colored
spheres and structural zinc ions are shown as grey spheres.
B The last ordered C-terminal residue of PatE′ is 26 Å distant from the nearest ATP (in the
other subunit to which the leader is bound) with a clear route through protein. Shielding of
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the α-phosphate precludes an adenylation mechanism. Magnesium ions are shown as grey
spheres.
C Difference electron density for LynD with AMP, Ca2+ions are shown as brown spheres,
atoms are colored as Fig 1C. Fo – Fc maps were contoured at 3σ with phases calculated
from a model, which was refined with no nucleotide or metal ions present after simulated
annealing (5000 K to 300 K in 100 K steps, Cartesian and torsion).
D Close up of nucleotide site, atoms colored as Fig 2C.
E LynD crystallized with ATP shows ADP, Pi and Mg2+ with maps calculated and atoms
colored as Fig 2C.
F Zoom view of Mg2+ coordination in Figure 2E.
G LynD with β,γ–imido-ATP and Mg2+ with maps calculated and atoms colored as Figure
2C.
H The peptide clamp between domains 1 (cyan) and 3 (green) that binds the PatE′ leader
peptide (yellow). Amino acids directly involved in substrate recognition are shown as sticks.
Koehnke et al. Page 18
Nat Chem Biol. Author manuscript.
 Europe PM
C
 Funders A
uthor M
anuscripts
 Europe PM
C
 Funders A
uthor M
anuscripts
Figure 3. The role of the substrate leader in promoting catalysis
A Relative rates of various cis and trans activated heterocyclization reactions analyzed by
MALDI TOF MS. The top graph shows the time taken to complete 1st heterocycle and the
bottom graph shows the time taken to form the 2nd heterocycle. Each time point was
analysed by three measurements, the experiment was repeated three times; thus each point
represents 9 measurements. Errors are plotted as ± 1 s.d..
B LCMS analysis of heterocyclization reactions of core peptide (ITACITFCAYDG)
incubated with TruD, LynD and LynDfusion. After 16 h core peptide incubated with either
TruD or LynD only 1 heterocycle is formed. In contrast when incubated with LynDfusion,
the heterocyclization reaction is nearly complete – the sample containing predominantly 2
heterocycles after just 2 h. PatE′ and LynD reaction after 2 h is shown as a reference.
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Figure 4. An engineered heterocyclase enzyme
Cartoon schematic highlighting the significant conformational rearrangement of the LynD
dimer (blue and green) following PatE′ binding (black), generating an ‘active’ enzyme. In
the absence of a leader peptide the conformational rearrangement is not possible and
heterocyclization of the core peptide is inefficient. In this way covalently bound leader
peptide (pink) in the LynDfusion mimics the ‘active’ enzyme, restoring efficient ‘wild type-
like’ processing of the core peptide.
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Table 1
Nucleotide binding and processing of LynD mutants
Enzyme
Nucleotide KD (μM)
No. of heterocycles (PatE′)
ATP AMP
LynD 50.25 14.41 2
LynD K409E no binding no binding 2
LynD K409A no binding no binding 1
LynD E423R no binding 5.65 0
LynD R427E no binding 23.04 1 and 2
LynD R636E no binding no binding 0, 1 and 2
LynD R636A N/A no binding 0, 1 and 2
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Table 2
LynD and PatE′ mutations and their effects on binding and processing
Enzyme Peptide KD (μM) No. of heterocycles
LynD PatE′ 1.49 2
LynD PatE′ L26R no binding 2
LynD PatE′ L29R no binding 1 and 2
LynD PatE′ E31R no binding 1 and 2
LynD PatE′ E32R 18.35 2
LynD Y67D PatE′ 12.92 2
LynD Y67D PatE′ L26R 15.22 2
LynD R74E PatE′ no binding 2
LynD R74E PatE′ E31R no binding 1 and 2
LynD R399E PatE′ 10.74 2
LynD R399E PatE′ E32R 8.55 2
LynD Fusion PatE′ 5.5 2
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